Literature DB >> 23949250

In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.

Vasco Filipe1, Ivo Que, John F Carpenter, Clemens Löwik, Wim Jiskoot.   

Abstract

PURPOSE: To monitor the biodistribution of IgG1 aggregates upon subcutaneous (SC) and intravenous (IV) administration in mice and measure their propensity to stimulate an early immune response.
METHODS: A human mAb (IgG1) was fluorescently labeled, aggregated by agitation stress and injected in SKH1 mice through SC and IV routes. The biodistribution of monomeric and aggregated formulations was monitored over 47 days by fluorescence imaging and the early immune response was measured by quantifying the level of relevant cytokines in serum using a Bio-plex assay.
RESULTS: The aggregates remained at the SC injection site for a longer time than monomers but after entry into the systemic circulation disappeared faster than monomers. Upon IV administration, both monomers and aggregates spread rapidly throughout the circulation, and a strong accumulation in the liver was observed for both species. Subsequent removal from the circulation was faster for aggregates than monomers. No accumulation in lymph nodes was observed after SC or IV administration. Administration of monomers and aggregates induced similar cytokine levels, but SC injection resulted in higher cytokine levels than IV administration.
CONCLUSION: These results show differences in biodistribution and residence time between IgG1 aggregates and monomers. The long residence time of aggregates at the SC injection site, in conjunction with elevated cytokine levels, may contribute to an enhanced immunogenicity risk of SC injected aggregates compared to that of monomers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23949250     DOI: 10.1007/s11095-013-1154-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  47 in total

1.  Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.

Authors:  Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 2.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

3.  Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway.

Authors:  James G Barnard; Satish Singh; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2010-08-27       Impact factor: 3.534

4.  Pipelines turn to biotech.

Authors:  Stacy Lawrence
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

5.  Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology.

Authors:  Yulia Vugmeyster; David DeFranco; Pamela Szklut; Qin Wang; Xin Xu
Journal:  J Pharm Sci       Date:  2010-02       Impact factor: 3.534

6.  Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2011-05-05       Impact factor: 4.200

Review 7.  Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen.

Authors:  B Bittner; W F Richter; F Hourcade-Potelleret; C McIntyre; F Herting; M L Zepeda; J Schmidt
Journal:  Arzneimittelforschung       Date:  2012-08-23

8.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation.

Authors:  Suzanne Hermeling; Huub Schellekens; Coen Maas; Martijn F B G Gebbink; Daan J A Crommelin; Wim Jiskoot
Journal:  J Pharm Sci       Date:  2006-05       Impact factor: 3.534

9.  Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice.

Authors:  Grzegorz Kijanka; Wim Jiskoot; Huub Schellekens; Vera Brinks
Journal:  Pharm Res       Date:  2013-01-30       Impact factor: 4.200

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  9 in total

1.  Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice.

Authors:  Angelika J Freitag; Maliheh Shomali; Stylianos Michalakis; Martin Biel; Michael Siedler; Zehra Kaymakcalan; John F Carpenter; Theodore W Randolph; Gerhard Winter; Julia Engert
Journal:  Pharm Res       Date:  2014-08-15       Impact factor: 4.200

Review 2.  Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.

Authors:  David M Francis; Susan N Thomas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

3.  Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans.

Authors:  Wolfgang F Richter; Hans-Peter Grimm; Marie-Hélène Gouy; Susi Søgaard; Caroline Kreuzer; Uwe Wessels; Dragomir Draganov; Chris Muenzer; Tonio Hoche
Journal:  AAPS J       Date:  2020-04-03       Impact factor: 4.009

4.  Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice.

Authors:  Carly Fleagle Chisholm; Abby E Baker; Kaitlin R Soucie; Raul M Torres; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2016-03-25       Impact factor: 3.534

Review 5.  Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

Authors:  Wim Jiskoot; Grzegorz Kijanka; Theodore W Randolph; John F Carpenter; Atanas V Koulov; Hanns-Christian Mahler; Marisa K Joubert; Vibha Jawa; Linda O Narhi
Journal:  J Pharm Sci       Date:  2016-04-01       Impact factor: 3.534

Review 6.  Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.

Authors:  William J Anderson; Natasha Ferreira Santos da Cruz; Luiz Henrique Lima; Geoffrey G Emerson; Eduardo Büchele Rodrigues; Gustavo Barreto Melo
Journal:  Int J Retina Vitreous       Date:  2021-05-07

7.  Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.

Authors:  J Benjamin St Clair; Thiago Detanico; Katja Aviszus; Greg A Kirchenbaum; Merry Christie; John F Carpenter; Lawrence J Wysocki
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

Review 8.  Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Nicole L Jarvi; Sathy V Balu-Iyer
Journal:  BioDrugs       Date:  2021-02-01       Impact factor: 5.807

9.  Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro.

Authors:  Verena Rombach-Riegraf; Anette C Karle; Babette Wolf; Laetitia Sordé; Stephan Koepke; Sascha Gottlieb; Jennifer Krieg; Marie-Claude Djidja; Aida Baban; Sebastian Spindeldreher; Atanas V Koulov; Andrea Kiessling
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.